PF-06260933 25 mg | Purity Not Available
TargetMol

PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
More Information Supplier PagePF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
More Information Supplier PagePF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
More Information Supplier PagePF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
More Information Supplier PageE6446 inhibits Toll-like receptor (TLR)7 and 9 signaling. E6446 works in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro. When administered to mice, this compound suppress responses to challenge doses of cytidine-phosphate-guanidine (CpG)-containing DNA, which stimulates TLR9.
More Information Supplier PageE6446 inhibits Toll-like receptor (TLR)7 and 9 signaling. E6446 works in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro. When administered to mice, this compound suppress responses to challenge doses of cytidine-phosphate-guanidine (CpG)-containing DNA, which stimulates TLR9.
More Information Supplier PagePF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
More Information Supplier PageKKL-10, a ribosome rescue inhibitor, has broad-spectrum antimicrobial activity against bacteria.
More Information Supplier PageKKL-10, a ribosome rescue inhibitor, has broad-spectrum antimicrobial activity against bacteria.
More Information Supplier PageVcMMAE is a drug-linker conjugate for ADC with potent antitumor activity.
More Information Supplier Page